CSL Behring’s one-time gene therapy for hemophilia, Hemgenix (etranacogene dezaparvovec), is to be made available to eligible patients in Spain after the country’s drug pricing committee, the CIPM, delivered a positive recommendation on national reimbursement.
The product, which has a list price of around $3.5m, was recommended at the committee’s 26 September meeting. Hemgenix has...







